SCHEMBL5741602

SCHEMBL5741602

CC(C)n1c(=O)n(F)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.47
POLB P06746 2/20 0.46
AR P10275 1/20 0.42
HTR4 Q13639 3/20 0.40
HTT P42858 1/20 0.38
SLC6A4 P31645 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7062555 0.85 SLC6A2 (0.56) SLC6A2POLBARHTR4HTT
SCHEMBL12139324 0.78 SLC6A2 (0.50) SLC6A2POLBHTR4
SCHEMBL27836296 0.76 POLB (0.53) SLC6A2POLBHTT
SCHEMBL13322673 0.76 POLB (0.46) SLC6A2POLBARHTR4HTT
SCHEMBL6909093 0.73 SLC6A2 (0.55) SLC6A2POLBSLC6A4
SCHEMBL24031446 0.72 GRM4 (0.53) SLC6A2POLBHTT
SCHEMBL12140924 0.72 SLC6A2 (0.43) SLC6A2POLBARHTR4SLC6A4
SCHEMBL2963786 0.72 HTR4 (0.53) SLC6A2POLBHTR4
SCHEMBL6584714 0.72 HTR4 (0.54) SLC6A2POLBHTR4
SCHEMBL5801271 0.71 HTR4 (0.52) SLC6A2POLBHTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732887-A1 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) Wyeth (US) 2006-12-20 EP disclosed
WO-2005097744-A1 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) WYETH (US) 2005-10-20 WO disclosed